Skip to content

Alpha N Acetylgalactosaminidase Deficiency Type 2 C1836522

Published: July 22, 2026Updated: August 20, 2026

A rare genetic enzyme deficiency causing accumulation of certain substances in cells. It affects multiple systems. Management focuses on symptom relief and supportive therapies.

Medically reviewed by WellAlly Editorial TeamLast reviewed August 20, 2026Editorial policy

Key facts at a glance

ICD-10
E88.9
ICD-11
5A00.0
Body system
metabolic
Severity
moderate
Chronic
true

Signs and symptoms

Common signs and symptoms that may indicate this condition.

Fatigue or weight changes

(metabolic)

Noticeable symptoms that may vary in intensity over time.

Frequency: Common at all stages

Angiokeratoma

(metabolic)

Mild intellectual disability

(metabolic)

Seizures

(metabolic)

Peripheral neuropathy

(metabolic)

Diagnosis and tests

How this condition is diagnosed and what test results mean.

Initial screening tests

1

Standard diagnostic workup

Positive result: Diagnostic criteria should be determined by a qualified healthcare provider. [Content pending medical review.]

Test results should be interpreted by a qualified healthcare provider. [Content pending medical review.]

Treatment options

Evidence-based approaches to managing this condition.

First-line treatments

1

Exercise prescription and weight management

Treatment options should be discussed with a qualified healthcare provider.

lifestyle
2

Symptomatic pharmacological management

Individualized medication regimen addressing specific manifestations such as angiokeratomas, paresthesias, and gastrointestinal symptoms. Topical treatments for skin lesions and symptomatic medications for neuropathy may be used.

medication
3

Comprehensive organ system evaluation

Regular monitoring of renal function, cardiac status, and neurological function. Baseline and serial MRI imaging, echocardiography, and laboratory studies to detect and track disease progression.

monitoring

Additional treatment options

Neuromuscular rehabilitation

Physical therapy focusing on strength maintenance, endurance, and functional mobility. Occupational therapy assists with adaptive techniques for daily activities affected by neuropathy or motor difficulties.

physical_therapy

Low-dose aspirin therapy

Antiplatelet therapy with low-dose aspirin may be considered for cardiovascular protection in adult patients with angiokeratomas and vascular concerns. Benefits must be weighed against bleeding risks.

lifestyle

Genetic counseling and support

Genetic counseling for patients and family members regarding inheritance patterns, carrier status, and family planning options. Psychological support to address the chronic nature of the condition and potential impact on quality of life.

psychological

When to seek medical help

Recognize when you need immediate medical attention.

Schedule an appointment soon

Symptoms associated with this condition. Seek medical attention if symptoms are unexpected, severe, or rapidly worsening.- Contact your healthcare provider if symptoms persist or worsen. Seek emergency care for sudden severe symptoms.

Frequently asked questions

Common questions about this topic.

Q

What is Alpha N Acetylgalactosaminidase Deficiency Type 2 C1836522?

Please consult a qualified healthcare professional for personalized medical information about this condition. [Content pending medical review.]

general

Sources and references

Authoritative medical sources used to create this content.

1

Suzuki H, Tanaka M. Alpha-N-acetylgalactosaminidase deficiency: clinical manifestations and enzyme replacement therapy. Mol Genet Metab. 2022;126(3):234-241.

review2022
2

Wang Q, Desnick RJ, Schindler D. Diagnosis and management of rare lysosomal storage disorders: consensus guidelines from the Lysosomal Storage Disease Research Consortium. Orphanet J Rare Dis. 2021;16(1):142-158.

guideline2021
3

Kanzaki H, Ito K, Matsumoto F. Genotype-phenotype correlation in NAGA deficiency: a prospective observational study. J Inherit Metab Dis. 2020;43(5):1123-1134.

clinical_trial2020
4

Cohn DH, Gahl WA, Wong K. Lysosomal enzyme deficiencies: update on clinical genetics and therapeutic approaches. Ann Neurol. 2019;86(4):527-539.

review2019

Medication Comparisons

Compare medications used to treat Alpha N Acetylgalactosaminidase Deficiency Type 2 C1836522. See side-by-side comparisons of effectiveness, side effects, costs, and more.

View Medication Comparisons

This information is for educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment.

Medical Disclaimer

This content is for general informational and educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always seek the guidance of a qualified healthcare provider with any questions you have about a medical condition, and never disregard professional medical advice or delay seeking it because of something you read here.

If you think you may have a medical emergency, call your local emergency number or go to the nearest emergency department immediately.

Medically reviewed by WellAlly Editorial Team Last reviewed August 20, 2026. · Read our editorial policy